1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 | On 06/17/2021, at 830am, Licensing Program Analyst (LPA) Misty Valencia conducted an unannounced Case Management visit and met with Administrator Janet Jones. Prior to initiating the visit, LPA completed required COVID-19 testing protocols, and a daily self-screening questionnaire for symptoms of COVID-19 infection to affirm no COVID-19 related symptoms; contacted Manager and completed a facility risk assessment. LPA ensured they applied hand sanitizer before entering the facility and the following Personal Protective Equipment (PPE) was worn: N-95 Masks, gloves, gown, and face shield. Additionally, LPA was screened by front desk personnel.
On 06/17/2021 LPA reviewed R1's medication records from 06/09-06/14/2021. The investigation revealed the following: R1 did not receive medication Lovenox that was prescribed on 06/09/2021 from Fairchild Medical Center (FMC). The facility failed to provide R1 with prescribed Levonox, 06/09-06/15, 2021, a total of 8 days of missed doses. Interviews with responsible personnel to include two (2) Medication Technicians, Administrator Janet Jones all confirmed R1 did not receive the prescribed medication because it is not a authorized medication that the facility should administer. Interviews confirmed the facility failed to obtain R1's medication, which resulted in the missed doses.
Based on the evidence obtained, the preponderance of evidence standard has been met, therefore the above allegation is found to be substantiated. California Code of Regulations, (Title 22), is being cited on the attached LIC 9099D.
Plan of correction (POC) were discussed. Appeal rights were provided and exit interview conducted |